Left behind: should minimal residual disease be treated in hairy cell leukemia?

References

• Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticulo-endotheliosis. Blood 1958;13:609–630.
   PubMed Web of Science ®Google Scholar
• Quesada JR, Reuben J, Manning JT, et al. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15–18.
   PubMed Web of Science ®Google Scholar
• Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2’-deoxycoformycin). J Clin Oncol 1984;2:1336–1342.
   PubMed Web of Science ®Google Scholar
• Piro LD, Carrera CJ, Carson DA, et al. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 1990;322:1117–1121.
   PubMed Web of Science ®Google Scholar
• Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21:891–896.
   PubMed Web of Science ®Google Scholar
• Chadha P, Rademaker AW, Mendiratta P, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood 2005;106: 241–246.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981–2986.
   PubMed Web of Science ®Google Scholar
• Else M, Ruchlemer R, Osuju N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 125 years. Cancer 2005;104:2442–2448.
   PubMed Web of Science ®Google Scholar
• Lopez Rubio M, Da Silva C, Loscertales J, et al. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). Leuk Lymphoma 2014;55:1007–1012
   PubMed Web of Science ®Google Scholar
• Sausville JE, Salloum RG, Sorbara L, et al. Minimal residual disease detection in hairy cell leukemia Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003;119:213–217.
   PubMed Web of Science ®Google Scholar
• Bengio R, Narbaitz MI, Sarmiento MA, et al. Comparative analysis of immunophenotypic methods for the assessment of minimal residual disease in hairy cell leukemia. Haematologica 2000;85:1227–1229.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999;5:1665–1670.
   PubMed Web of Science ®Google Scholar
• Sigal DS, Sharpe R, Burian C, et al. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893–1896.
   PubMed Web of Science ®Google Scholar
• Ellison DJ, Sharpe RW, Robbins BA, et al. Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 1994;84:4310–4315.
   PubMed Web of Science ®Google Scholar
• Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4 + lymphocytopenia after treatment. Leuk Lymphoma 1999;35: 555–565.
   PubMed Web of Science ®Google Scholar
• Wheaton S, Tallman MS, Hakimian D, et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996;87: 1556–1560.
   PubMed Web of Science ®Google Scholar
• Matutes E, Meeus P, McLennan K, et al. The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. Br J Haematol 1997;98:375–383.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658–4662.
   PubMed Web of Science ®Google Scholar
• Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. Br J Haematol 2008;143:296–298.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Sciavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305–2315.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012;119:188–191.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Haferlach T, et al. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood 2012;119: 3151–3154.
   PubMed Web of Science ®Google Scholar
• Akarca AU, Shende VH, Ramsay AD, et al. BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia. Br J Haematol 2013;162: 848–851.
   PubMed Web of Science ®Google Scholar
• Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366:2038–2040.
   PubMed Web of Science ®Google Scholar
• Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol 2013;31:e351–e352.
   PubMed Web of Science ®Google Scholar